Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation

J. Nemunaitis, F. R. Appelbaum, J. W. Singer, K. Lilleby, S. Wolff, J. P. Greer, Philip Jay Bierman, D. Resta, M. Campion, D. Levitt, Z. Zeigler, C. Rosenfeld, R. K. Shadduck, C. D. Buckner

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Recombinant human interleukin-3 (rhIL-3) was administered to 30 patients undergoing autologous bone marrow transplant (ABMT) for treatment of lymphoma. In this phase I dose escalation study, rhIL-3 was administered from day 0 to 20 after ABMT by 2-hour intravenous infusion at dose levels of 1, 2, 5, and 10 μg/kg/d. Seventeen patients did not complete therapy with rhIL-3. Eleven requested early discontinuation for malaise,6 confusion,1 transplant complications,3 or rapid engraftment1 and were removed from the study, whereas six patients developed grade III toxicity, including fever (three patients), or headache (three patients) possibly attributable to rhIL3. Other common toxicities included diarrhea, rigors, mucositis, and rash. The maximum tolerated dose of rhIL-3 was 2 μg/kg/d. No evidence of earlier hematopoietic cell recovery was observed compared with similar historical patients treated with recombinant human granulocyte-macrophage colony-stimulating factor. Future trials will be needed to determine alternate schedules of administration of rhIL-3 or the use of rhIL-3 in combination or in sequence with other growth factors.

Original languageEnglish (US)
Pages (from-to)3273-3278
Number of pages6
JournalBlood
Volume82
Issue number11
StatePublished - Jan 1 1993

Fingerprint

Autologous Transplantation
Interleukin-3
Bone Marrow Transplantation
Lymphoma
Bone
Transplants
Toxicity
Bone Marrow
Mucositis
Granulocyte-Macrophage Colony-Stimulating Factor
Maximum Tolerated Dose
Exanthema
Intravenous Infusions
Intercellular Signaling Peptides and Proteins
Headache
Diarrhea
Appointments and Schedules
Fever
Recovery
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Nemunaitis, J., Appelbaum, F. R., Singer, J. W., Lilleby, K., Wolff, S., Greer, J. P., ... Buckner, C. D. (1993). Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood, 82(11), 3273-3278.

Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. / Nemunaitis, J.; Appelbaum, F. R.; Singer, J. W.; Lilleby, K.; Wolff, S.; Greer, J. P.; Bierman, Philip Jay; Resta, D.; Campion, M.; Levitt, D.; Zeigler, Z.; Rosenfeld, C.; Shadduck, R. K.; Buckner, C. D.

In: Blood, Vol. 82, No. 11, 01.01.1993, p. 3273-3278.

Research output: Contribution to journalArticle

Nemunaitis, J, Appelbaum, FR, Singer, JW, Lilleby, K, Wolff, S, Greer, JP, Bierman, PJ, Resta, D, Campion, M, Levitt, D, Zeigler, Z, Rosenfeld, C, Shadduck, RK & Buckner, CD 1993, 'Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation', Blood, vol. 82, no. 11, pp. 3273-3278.
Nemunaitis J, Appelbaum FR, Singer JW, Lilleby K, Wolff S, Greer JP et al. Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood. 1993 Jan 1;82(11):3273-3278.
Nemunaitis, J. ; Appelbaum, F. R. ; Singer, J. W. ; Lilleby, K. ; Wolff, S. ; Greer, J. P. ; Bierman, Philip Jay ; Resta, D. ; Campion, M. ; Levitt, D. ; Zeigler, Z. ; Rosenfeld, C. ; Shadduck, R. K. ; Buckner, C. D. / Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. In: Blood. 1993 ; Vol. 82, No. 11. pp. 3273-3278.
@article{a95bba8d47c64cbf968c64fccc2f4378,
title = "Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation",
abstract = "Recombinant human interleukin-3 (rhIL-3) was administered to 30 patients undergoing autologous bone marrow transplant (ABMT) for treatment of lymphoma. In this phase I dose escalation study, rhIL-3 was administered from day 0 to 20 after ABMT by 2-hour intravenous infusion at dose levels of 1, 2, 5, and 10 μg/kg/d. Seventeen patients did not complete therapy with rhIL-3. Eleven requested early discontinuation for malaise,6 confusion,1 transplant complications,3 or rapid engraftment1 and were removed from the study, whereas six patients developed grade III toxicity, including fever (three patients), or headache (three patients) possibly attributable to rhIL3. Other common toxicities included diarrhea, rigors, mucositis, and rash. The maximum tolerated dose of rhIL-3 was 2 μg/kg/d. No evidence of earlier hematopoietic cell recovery was observed compared with similar historical patients treated with recombinant human granulocyte-macrophage colony-stimulating factor. Future trials will be needed to determine alternate schedules of administration of rhIL-3 or the use of rhIL-3 in combination or in sequence with other growth factors.",
author = "J. Nemunaitis and Appelbaum, {F. R.} and Singer, {J. W.} and K. Lilleby and S. Wolff and Greer, {J. P.} and Bierman, {Philip Jay} and D. Resta and M. Campion and D. Levitt and Z. Zeigler and C. Rosenfeld and Shadduck, {R. K.} and Buckner, {C. D.}",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
volume = "82",
pages = "3273--3278",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation

AU - Nemunaitis, J.

AU - Appelbaum, F. R.

AU - Singer, J. W.

AU - Lilleby, K.

AU - Wolff, S.

AU - Greer, J. P.

AU - Bierman, Philip Jay

AU - Resta, D.

AU - Campion, M.

AU - Levitt, D.

AU - Zeigler, Z.

AU - Rosenfeld, C.

AU - Shadduck, R. K.

AU - Buckner, C. D.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Recombinant human interleukin-3 (rhIL-3) was administered to 30 patients undergoing autologous bone marrow transplant (ABMT) for treatment of lymphoma. In this phase I dose escalation study, rhIL-3 was administered from day 0 to 20 after ABMT by 2-hour intravenous infusion at dose levels of 1, 2, 5, and 10 μg/kg/d. Seventeen patients did not complete therapy with rhIL-3. Eleven requested early discontinuation for malaise,6 confusion,1 transplant complications,3 or rapid engraftment1 and were removed from the study, whereas six patients developed grade III toxicity, including fever (three patients), or headache (three patients) possibly attributable to rhIL3. Other common toxicities included diarrhea, rigors, mucositis, and rash. The maximum tolerated dose of rhIL-3 was 2 μg/kg/d. No evidence of earlier hematopoietic cell recovery was observed compared with similar historical patients treated with recombinant human granulocyte-macrophage colony-stimulating factor. Future trials will be needed to determine alternate schedules of administration of rhIL-3 or the use of rhIL-3 in combination or in sequence with other growth factors.

AB - Recombinant human interleukin-3 (rhIL-3) was administered to 30 patients undergoing autologous bone marrow transplant (ABMT) for treatment of lymphoma. In this phase I dose escalation study, rhIL-3 was administered from day 0 to 20 after ABMT by 2-hour intravenous infusion at dose levels of 1, 2, 5, and 10 μg/kg/d. Seventeen patients did not complete therapy with rhIL-3. Eleven requested early discontinuation for malaise,6 confusion,1 transplant complications,3 or rapid engraftment1 and were removed from the study, whereas six patients developed grade III toxicity, including fever (three patients), or headache (three patients) possibly attributable to rhIL3. Other common toxicities included diarrhea, rigors, mucositis, and rash. The maximum tolerated dose of rhIL-3 was 2 μg/kg/d. No evidence of earlier hematopoietic cell recovery was observed compared with similar historical patients treated with recombinant human granulocyte-macrophage colony-stimulating factor. Future trials will be needed to determine alternate schedules of administration of rhIL-3 or the use of rhIL-3 in combination or in sequence with other growth factors.

UR - http://www.scopus.com/inward/record.url?scp=0027368563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027368563&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 3273

EP - 3278

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -